Ecovyst (ECVT) investor relations material

Executive summary

• Q2 2026 sales increased 42% year-over-year to $250 million, driven by higher sulfuric acid volumes, favorable pricing, and contributions from recent acquisitions including Calabrian and Waggaman.

• Adjusted EBITDA grew 27% to $53.1 million, supported by robust demand and pricing, despite inflationary pressures.

• Net income from continuing operations more than doubled to $10.7 million, with adjusted net income at $23.4 million.

• Closed the Calabrian acquisition on June 30, 2026, expanding the sulfur chemistries portfolio and expected to contribute $10–$12 million Adjusted EBITDA in H2 2026.

• Integration of Calabrian is on track, with synergy actions underway and growth projects identified.

Financial highlights

• Q2 2026 sales: $250 million (up $73.9 million or 42% year-over-year); Adjusted EBITDA: $53.1 million (up 26.7%); Adjusted Free Cash Flow for H1 2026: $13 million.

• Net income for Q2 2026: $10.7 million; Adjusted Net Income: $23.4 million; Adjusted Diluted EPS: $0.21.

• Gross profit: $49.8 million; gross margin: 19.9%; Adjusted EBITDA margin: 21.2%.

• Net debt leverage ratio at quarter end: 2.0x; available liquidity: $176 million ($88 million cash, $88 million ABL availability).

• Net debt as of June 30, 2026: $409.3 million; total debt: $497.1 million.

Outlook and guidance

• Full-year 2026 sales guidance raised to $1,020–$1,060 million, including Calabrian.

• Full-year Adjusted EBITDA guidance increased to $195–$207 million; Adjusted Free Cash Flow: $45–$55 million.

• Adjusted Net Income guidance: $65–$85 million; Adjusted EPS: $0.58–$0.72.

• Capital expenditures projected at $85–$95 million; D&A at $80–$84 million; effective tax rate in the mid-20% range.

• Q3 2026 Adjusted EBITDA (including Calabrian): $54–$59 million; Q4: $48–$55 million.